Craig Coleman
Professor/Pharmacy Practice
Storrs Mansfield
Are you Craig Coleman?
How to update your information.
Scholarly Contributions
620 Scholarly Contributions
Walking Speed and Health-Related Quality of Life in Multiple Sclerosis.
2013
Research Type: Journal Article
Weekly Risk of Venous Thromboembolism Recurrence in Patients Receiving Oral Anticoagulants.
2014
Research Type: Journal Article
What Are the Effects of Nonsteroidal Anti-Inflammatory Drugs on Post-Cardiothoracic Surgery Outcomes?
2007
Research Type: Other Scholarly Work
What Characteristics of Schools/Colleges of Pharmacy Drive ‘US News and World Report’ Rankings?
2012
Research Type: Poster/Presentation
What Proportion of Hospitalizations in Acute Medically Ill Patients Qualify for Extended Thromboprophylaxis with Oral Anticoagulation?
2019
Research Type: Poster/Presentation
Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.
2022
Research Type: Journal Article
ale to the EuroQol 5-Dimension Index Measure in North American Multiple Sclerosis Patients MMapping the 12-Item Multiple Sclerosis Walking Scale to the EuroQol 5-Dimension Index Measure in North American Multiple Sclerosis Patients
2012
Research Type: Poster/Presentation
niversal Versus Platelet Reactivity Assay-Driven Use of P2Y12 Inhibitors in Acute Coronary Syndrome Patients: Cost-Effectiveness Analyses from Five European Perspectives
2013
Research Type: Poster/Presentation
“Advantages of Once Daily Dosing on Medication Adherence and Persistence”.
2017
Research Type: Poster/Presentation
“Case clinic sessions: Tackling the challenge: High-risk NVAF patients”
2019
Research Type: Poster/Presentation
“Effectiveness and Safety of Rivaroxaban and Warfarin for Prevention of Major Adverse Cardiovascular or Limb Events in Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes”. Event: ISTH 2019, Melbourne.
2019
Research Type: Poster/Presentation
“Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease”. Event: ESC Congress 2019, Paris.
2019
Research Type: Poster/Presentation
“FOUR-YEAR INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ATRIAL FIBRILLATION PATIENTS WITH OR AT HIGH RISK FOR ATHEROSCLEROSIS”. Event: ACC 2020, Chicago.
2020
Research Type: Poster/Presentation
“Four-Year Incidence of Major Adverse Cardiovascular Events in Patients With Established Cerebrovascular Disease”. Event: ISC 2020, Los Angeles.
2020
Research Type: Poster/Presentation
“OUTCOMES ASSOCIATED WITH BLEEDING-RELATED HOSPITALIZATIONS IN PATIENTS AT HIGH THROMBOTIC RISK FINDINGS FROM THE NATIONWIDE READMISSION DATABASE”. Event: ACC 2020, Chicago.
2020
Research Type: Poster/Presentation
“REAL-WORLD MANAGEMENT OF ORAL FACTOR XA INHIBITOR BLEEDING-RELATED HOSPITALIZATIONS WITH ANDEXANET ALFA OR 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE”. Event: ACC 2020, Chicago.
2020
Research Type: Poster/Presentation
“RIVAROXABAN VERSUS WARFARIN IN AFRICAN AMERICAN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION”. Event: ACC 2020, Chicago.
2020
Research Type: Poster/Presentation
“Rivaroxaban Versus Warfarin and Renal Outcomes in Non-valvular Atrial Fibrillation Patients with Diabetes”. Event: ISTH 2019, Melbourne.
2019
Research Type: Poster/Presentation